306 related articles for article (PubMed ID: 22042316)
1. [Translational medicine].
Antal J; Timár A
Orv Hetil; 2011 Nov; 152(47):1894-902. PubMed ID: 22042316
[TBL] [Abstract][Full Text] [Related]
2. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
3. Market watch: Upcoming market catalysts in Q2 2013.
Nguyen K
Nat Rev Drug Discov; 2013 Apr; 12(4):254. PubMed ID: 23535926
[No Abstract] [Full Text] [Related]
4. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
5. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
6. Innovative approaches in drug development.
Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
[TBL] [Abstract][Full Text] [Related]
7. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.
Feuerstein GZ; Zaleska MM; Krams M; Wang X; Day M; Rutkowski JL; Finklestein SP; Pangalos MN; Poole M; Stiles GL; Ruffolo RR; Walsh FL
J Cereb Blood Flow Metab; 2008 Jan; 28(1):217-9. PubMed ID: 17579658
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
9. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
10. Bioethics and post-approval research in translational science.
Chen JY; Carter M
Am J Bioeth; 2010 Aug; 10(8):35-7. PubMed ID: 20694904
[No Abstract] [Full Text] [Related]
11. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
Sakamoto J; Morita S
Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
[TBL] [Abstract][Full Text] [Related]
12. Mitigating administrative risks in industry-sponsored clinical trials.
Kim PJ
J Foot Ankle Surg; 2011; 50(6):633-4. PubMed ID: 21908208
[No Abstract] [Full Text] [Related]
13. The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface.
Enna SJ; Williams M
Adv Pharmacol; 2009; 57():xi-ii. PubMed ID: 19945649
[No Abstract] [Full Text] [Related]
14. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
15. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
16. The structure of clinical translation: efficiency, information, and ethics.
Kimmelman J; London AJ
Hastings Cent Rep; 2015; 45(2):27-39. PubMed ID: 25628068
[TBL] [Abstract][Full Text] [Related]
17. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
[No Abstract] [Full Text] [Related]
18. Overhauling clinical trials.
Scott CT; Baker M
Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
[No Abstract] [Full Text] [Related]
19. Ethical dilemmas encountered during clinical drug trials.
Daicos GK
Hum Health Care; 2001; 1(2):E9. PubMed ID: 14986633
[TBL] [Abstract][Full Text] [Related]
20. FDA perspective on specifications for biotechnology products--from IND to PLA.
Murano G
Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
